MedTrace Logo

Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack With an Intelligent Management System

NCT06783049 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4490

Last updated 2026-01-21

No results posted yet for this study

Summary

The purpose of this study is to develop a digital health-based intelligent management system for the secondary prevention of ischemic stroke and to evaluate its effectiveness through a multicenter randomized controlled trial, assessing its health economic value.

Participants will receive usual care after discharge (control group) or be managed with a WeChat-based intelligent management system after discharge (intervention group).

At one year, all patients will undergo face-to-face follow-up to assess clinical events, medication adherence, and the achievement of target risk factor levels.

Conditions

Interventions

BEHAVIORAL

Cerebrovascular Disease Secondary Prevention Smart Management System

The continuous post-discharge intervention for patients was conducted using the Cerebrovascular Disease Secondary Prevention Smart Management System. This system, integrated with a WeChat-based applet, records patients' basic information and connects with mobile IoT devices such as blood pressure monitors and glucose meters. This allows patients to self-monitor their risk factors post-discharge. Based on international guidelines, high-level evidence, and the clinical expertise of cerebrovascular specialists, a comprehensive clinical decision-making tree was developed. This serves as the foundation for an AI feedback system that provides intelligent feedback on risk factor control and predicts the risk of recurrence.

Sponsors & Collaborators

  • Beijing Tsinghua Chang Gung Hospital

    collaborator OTHER

  • Xiangya Hospital of Zhongnan University

    collaborator UNKNOWN

  • The affiliated Hospital of Shihezi University

    collaborator UNKNOWN

  • The First Hospital of Jilin University

    collaborator OTHER

  • First People's Hospital of Foshan

    collaborator OTHER

  • The Second Affiliated Hospital of Fujian Medical University

    collaborator OTHER

  • BOE Technology Group Co. Ltd.

    collaborator UNKNOWN

  • Beijing Tiantan Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-03
Primary Completion
2026-12-31
Completion
2027-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06783049 on ClinicalTrials.gov